Skip to main content
Hualan Biological Engineering Inc. logo

Hualan Biological Engineering Inc. — Investor Relations & Filings

Ticker · 002007 ISIN · CNE000001JN8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,526 across all filing types
Latest filing 2019-08-29 Interim / Quarterly Rep…
Country CN China
Listing Shenzhen Stock Exchange 002007

About Hualan Biological Engineering Inc.

https://www.hualanbio.com

Hualan Biological Engineering Inc. is a biopharmaceutical enterprise specializing in the research, development, production, and commercialization of blood products and vaccines. The company’s portfolio is divided into two primary segments: plasma-derived therapeutics and viral vaccines. Key blood products include human albumin, intravenous immunoglobulin (IVIG), human coagulation factor VIII, and prothrombin complex. In the vaccine sector, the company produces seasonal influenza vaccines, including quadrivalent formulations, as well as hepatitis B and rabies vaccines. Hualan Biological Engineering operates advanced manufacturing facilities and plasma collection centers, focusing on high-quality standards and technological innovation in recombinant protein drugs and monoclonal antibodies to address critical medical needs in immunology, hematology, and infectious disease prevention.

Recent filings

Filing Released Lang Actions
财务报告
Interim / Quarterly Report Classification · 95% confidence The document contains detailed financial statements for the period January to June 2019, including consolidated balance sheets, profit and loss statements, cash flow statements, and changes in shareholders' equity. The presence of comprehensive financial data and analysis for a half-year period indicates this is an interim or quarterly financial report. The document is about 15,000 characters long, which is consistent with a full report rather than a brief announcement or certification. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). H1 2019
2019-08-29 Chinese
2019年半年度报告摘要
Interim / Quarterly Report Classification · 100% confidence The document is titled as a '2019 半年度报告摘要' which translates to '2019 Semi-Annual Report Summary'. It contains detailed financial data such as revenue, net profit, earnings per share, and asset information for the half-year period. It also discusses accounting policy changes and operational highlights for the reporting period. The length of the document (10,486 characters) and the presence of substantive financial data and analysis confirm it is a comprehensive financial report for a period shorter than a full fiscal year. Therefore, it fits the definition of an Interim / Quarterly Report (IR). H1 2019
2019-08-29 Chinese
独立董事关于控股股东及其他关联方占用公司资金、公司对外担保情况的专项说明和独立意见
Regulatory Filings Classification · 95% confidence The document is a special statement and independent opinion by independent directors regarding the company's related party fund occupation and external guarantees. It references regulatory notices and compliance with rules but does not contain financial statements or detailed financial data. The document is short (617 characters) and serves as a regulatory compliance statement rather than a full report. It fits best under Regulatory Filings (RNS) as it is a compliance-related announcement without substantive financial data or report content.
2019-08-29 Chinese
2019年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled as the "2019 年半年度报告全文" which translates to "2019 Semi-Annual Report Full Text." It contains detailed financial data, business overview, management discussion and analysis, financial indicators, and other comprehensive information typical of an interim or quarterly report. The report period is clearly stated as the first half of 2019 (2019年半年度). The document includes actual financial statements, detailed analysis of business segments, profit and loss, cash flows, and asset/liability status. It is not a brief announcement or a certification letter but a full report. Therefore, it fits the definition of an Interim / Quarterly Report (IR). H1 2019
2019-08-29 Chinese
关于部分高管减持计划期满未实施减持的公告
Director's Dealing Classification · 95% confidence The document is a public announcement from a company regarding the expiration of a planned share reduction by a senior executive that was not executed. It references regulatory compliance with stock exchange rules and securities laws, and details the non-implementation of a previously disclosed share reduction plan. The document is short (1108 characters) and serves as an update on insider share transactions rather than a full report or financial statement. This fits the definition of a Director's Dealing (DIRS) filing, which reports personal share transactions by company directors and executives.
2019-07-01 Chinese
关于控股子公司流感车间通过GMP认证的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (395 characters) about a subsidiary passing GMP certification for a vaccine production line. It is an official company announcement but does not contain financial data, management changes, voting results, or detailed reports. It is not a report itself but a regulatory announcement about certification. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement.
2019-06-27 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.